DDrare: Database of Drug Development for Rare Diseases

Searched query = "Achondroplasia"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = Active BMN 111: Daily subcutaneous injection of 15 ug/kg of BMN 111; BGJ398 (also known as BBP-831); BMN 111; C-TYPE NATRIURETIC PEPTIDE CONJUGATED TO MULTI-ARM POLYETHYLENE GLYCOL CARRIER THROUGH A CLEAVABLE LINKER; INFIGRATINIB; Infigratinib; Infigratinib 0.016 mg/kg; Infigratinib 0.032 mg/kg; Infigratinib 0.064 mg/kg; Infigratinib 0.128 mg/kg; Infigratinib phosphate; MODIFIED RHCNP; Modified recombinant human C-type natriuretic peptide; Modified recombinant human c-type; Natriuretic peptide; Normal Saline; PF-07256472; Phosphate; Placebo; Polyethylene glycol; Recifercept; Recifercept (proposed INN); Somatropin; TA-46; TBD; TransCon CNP; TransCon CNP 3.9 mg CNP-38/vial; Vorsoritide; Vosoritide

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01435629 (ClinicalTrials.gov)	November 22, 2012	14/9/2011	A Survey Collecting Data on Adult Height in Patients With Achondroplasia Treated With Somatropin	Open-label, Multicenter, Observational, Non-intervention Study to Retrospectively Evaluate the Efficacy of Norditropin® (Adult Height) in Patients With Achondroplasia/Hypochondroplasia Enrolled in the GH-1941 Study [Follow-up Survey]	Genetic Disorder;Achondroplasia	Drug: somatropin	Novo Nordisk A/S	NULL	Completed	N/A	N/A	All	81	N/A	Japan
2	NCT01516229 (ClinicalTrials.gov)	May 1, 1997	19/1/2012	Special Survey for Long Term Application	Specific Survey of Norditropin® in Achondroplasia: Survey for Long-term Application	Genetic Disorder;Achondroplasia	Drug: somatropin	Novo Nordisk A/S	NULL	Completed	1 Year	15 Years	All	395	N/A	Japan

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT01435629
(ClinicalTrials.gov)

November 22, 2012

14/9/2011

A Survey Collecting Data on Adult Height in Patients With Achondroplasia Treated With Somatropin

Open-label, Multicenter, Observational, Non-intervention Study to Retrospectively Evaluate the Efficacy of Norditropin® (Adult Height) in Patients With Achondroplasia/Hypochondroplasia Enrolled in the GH-1941 Study [Follow-up Survey]

Genetic Disorder;Achondroplasia

Drug: somatropin

Novo Nordisk A/S

NULL

Completed

N/A

All

N/A

Japan

NCT01516229
(ClinicalTrials.gov)

May 1, 1997

19/1/2012

Special Survey for Long Term Application

Specific Survey of Norditropin® in Achondroplasia: Survey for Long-term Application